BBIO
BRIDGEBIO PHARMA INCData as of 2026 Q2 (06-30) · 13F snapshot
Summary
BRIDGEBIO PHARMA INC (BBIO) is held as common stock by 7 tracked hedge-fund managers, with a combined reported value of ~$1.27B; the largest are Andreas Halvorsen, Ken Griffin, Steven Cohen. 4 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 2 new, 3 added, 2 trimmed. 8 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Heating up
Common-stock holders74 also report options
Congress trades8
Price$65.97vs quarter-end-11.43%
Sectors0
This quarter's moves
Top holderNew2
Added3
Trimmed / sold2
Andreas HalvorsenCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
Value $741.02M2.1% of portfolio9,949,2192026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Andreas Halvorsen | $741.02M | 2.1% | Trim |
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $21.28M— of portfolio285,7002026 Q2
Value $20.94M— of portfolio281,2002026 Q2
Value $13.57M— of portfolio182,2002026 Q2
Value $2.42M— of portfolio32,5002026 Q2
Value $521.4K— of portfolio7,0002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $21.28M | — | — |
| Ken GriffinPUT | $20.94M | — | — |
| Izzy EnglanderCALL | $13.57M | — | — |
| Paul Tudor JonesCALL | $2.42M | — | — |
| Steven CohenCALL | $521.4K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.